| Acute headache medication users at baseline | Users of migraine-specific medicine at baseline | Non-users of migraine-specific medicine at baseline | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Episodic migraine | |||||||||||
 | Placebo (N = 315) | 70 mg (N = 305) | 140 mg (N = 312) | Placebo (N = 191) | 70 mg (N = 179) | 140 mg (N = 192) | Placebo (N = 124) | 70 mg (N = 126) | 140 mg (N = 120) | ||
Demographics | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Age, years (range) | 41.3 ± 11.2 (18–65) | 41.2 ± 11.2 (18–63) | 40.4 ± 11.1 (19–65) | 43.3 ± 10.9 (18–65) | 43.8 ± 11 (18–63) | 42 ± 10.7 (19–65) | 38.4 ± 11 (18–64) | 37.5 ± 10.6 (19–63) | 37.9 ± 11.4 (19–62) | ||
Female, n (%) | 271 (86.0) | 261 (85.6) | 266 (85.3) | 164 (85.9) | 152 (84.9) | 169 (88) | 107 (86.3) | 109 (86.5) | 97 (80.8) | ||
Caucasian, n (%) | 274 (87.0) | 274 (89.8) | 288 (92.3) | 180 (94.2) | 173 (96.6) | 184 (95.8) | 94 (75.8) | 101 (80.2) | 104 (86.7) | ||
Baseline characteristics | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Monthly migraine days | 8.3 ± 2.5 | 8.3 ± 2.5 | 8.3 ± 2.5 | 8.5 ± 2.5 | 8.4 ± 2.5 | 8.5 ± 2.4 | 7.9 ± 2.5 | 8.0 ± 2.3 | 8.1 ± 2.5 | ||
Monthly headache days | 9.3 ± 2.6 | 9.0 ± 2.6 | 9.3 ± 2.5 | 9.3 ± 2.6 | 9.0 ± 2.6 | 9.3 ± 2.5 | 9.3 ± 2.6 | 9.0 ± 2.6 | 9.2 ± 2.6 | ||
Monthly migraine-specific medication days | 3.5 ± 3.4 | 3.3 ± 3.4 | 3.5 ± 3.5 | 5.7 ± 2.6 | 5.7 ± 2.5 | 5.7 ± 2.7 | 0 | 0 | 0 | ||
Age at migraine onset | 21.2 ± 10.1 | 21.2 ± 11 | 20.7 ± 9.9 | 20.6 ± 10.2 | 21.5 ± 11.4 | 21.2 ± 9.8 | 22.0 ± 10 | 20.7 ± 10.5 | 20.0 ± 10.2 | ||
Disease duration, years | 20.2 ± 12.2 | 20.1 ± 12.2 | 19.8 ± 12.3 | 22.7 ± 11.9 | 22.4 ± 12.1 | 20.9 ± 12.2 | 16.4 ± 11.5 | 16.8 ± 11.5 | 18.0 ± 12.3 | ||
Acute headache medication use, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Any | 315 (100) | 305 (100) | 312 (100) | 191 (100) | 179 (100) | 192 (100) | 124 (100.0) | 126 (100.0) | 120 (100.0) | ||
Migraine-specific | 191 (60.6) | 179 (58.7) | 192 (61.5) | 191 (100) | 179 (100) | 192 (100) | 0 (0) | 0 (0) | 0 (0) | ||
Non-migraine-specific | 244 (77.5) | 242 (79.3) | 256 (82.1) | 120 (62.8) | 116 (64.8) | 136 (70.8) | 124 (100.0) | 126 (100.0) | 120 (100.0) | ||
Migraine-preventive medication use, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Naïve | 174 (55.2) | 164 (53.8) | 184 (59.0) | 84 (44) | 73 (40.8) | 87 (45.3) | 90 (72.6) | 91 (72.2) | 97 (80.8) | ||
Previous | 131 (41.6) | 132 (43.3) | 120 (38.5) | 100 (52.4) | 100 (55.9) | 100 (52.1) | 31 (25.0) | 32 (25.4) | 20 (16.7) | ||
History of treatment failure of preventive medication* | 127 (40.3) | 126 (41.3) | 112 (35.9) | 98 (54.7) | 98 (54.7) | 92 (47.9) | 28 (22.6) | 28 (22.2) | 20 (16.7) | ||
History of migraine with aura, n (%) | 160 (50.8) | 162 (53.1) | 157 (50.3) | 82 (42.9) | 82 (45.8) | 84 (43.8) | 78 (62.9) | 80 (63.5) | 73 (60.8) | ||
Chronic migraine | |||||||||||
 | Placebo (N = 282) | 70 mg (N = 191) | 140 mg (N = 188) | Placebo (N = 225) | 70 mg (N = 143) | 140 mg (N = 149) | Placebo (N = 57) | 70 mg (N = 48) | 140 mg (N = 39) | ||
Demographics | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Age, years (range) | 42.2 ± 11.3 (18–66) | 41.4 ± 11.3 (18–64) | 43.1 ± 11 (18–64) | 43.4 ± 11.1 (18–66) | 42.5 ± 11 (18–64) | 44.4 ± 10.3 (18–64) | 37.7 ± 11 (18–64) | 38.1 ± 11.7 (18–58) | 38.3 ± 12.3 (20–58) | ||
Female, n (%) | 223 (79.1) | 166 (86.9) | 158 (84) | 175 (77.8) | 126 (88.1) | 134 (89.9) | 48 (84.2) | 40 (83.3) | 24 (61.5) | ||
Caucasian, n (%) | 264 (93.6) | 176 (92.1) | 182 (96.8) | 215 (95.6) | 134 (93.7) | 146 (98) | 49 (86) | 42 (87.5) | 36 (92.3) | ||
Baseline characteristics | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Monthly migraine days | 18.2 ± 4.7 | 17.9 ± 4.4 | 17.7 ± 4.6 | 18.2 ± 4.6 | 18.1 ± 4.4 | 17.7 ± 4.3 | 18.1 ± 5.3 | 17.1 ± 4.4 | 17.5 ± 5.9 | ||
Monthly headache days | 21.1 ± 3.9 | 20.5 ± 3.8 | 20.7 ± 3.8 | 20.9 ± 3.8 | 20.6 ± 3.8 | 20.3 ± 3.7 | 21.8 ± 4.3 | 20.3 ± 4 | 21.9 ± 3.8 | ||
Monthly migraine-specific medication days | 9.6 ± 7.6 | 8.8 ± 7.2 | 9.8 ± 7.0 | 12.0 ± 6.5 | 11.7 ± 5.8 | 12.3 ± 5.5 | 0 | 0 | 0 | ||
Age at migraine onset | 20.3 ± 10.0 | 21.1 ± 10.5 | 21.5 ± 10.7 | 20.7 ± 10.1 | 19.9 ± 10.2 | 21.1 ± 10.8 | 18.8 ± 9.4 | 24.7 ± 10.9 | 23.2 ± 10.4 | ||
Disease duration, years | 22.4 ± 12.6 | 20.7 ± 12.8 | 22.1 ± 11.8 | 23.1 ± 12.8 | 23.0 ± 12.9 | 23.8 ± 11.2 | 19.4 ± 11.7 | 13.9 ± 10.2 | 15.6 ± 11.9 | ||
Acute headache medication use, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Any | 282 (100) | 191 (100) | 188 (100) | 225 (100) | 143 (100) | 149 (100) | 57 (100) | 48 (100) | 39 (100) | ||
Migraine-specific | 225 (79.8) | 143 (74.9) | 149 (79.3) | 225 (100) | 143 (100) | 149 (100) | 0 (0) | 0 (0) | 0 (0) | ||
Non-migraine-specific | 246 (87.2) | 167 (87.4) | 161 (85.6) | 189 (84) | 119 (83.2) | 122 (81.9) | 57 (100) | 48 (100) | 39 (100) | ||
Migraine-preventive medication use, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
Naïve | 67 (23.8) | 53 (27.7) | 54 (28.7) | 41 (18.2) | 31 (21.7) | 31 (20.8) | 26 (45.6) | 22 (45.8) | 23 (59.0) | ||
Previous | 215 (76.2) | 138 (72.3) | 134 (71.3) | 184 (81.8) | 112 (78.3) | 118 (79.2) | 31 (54.4) | 26 (54.2) | 16 (41.0) | ||
History of treatment failure of preventive medicationa | 198 (70.2) | 127 (66.5) | 124 (66) | 170 (75.6) | 105 (93.8) | 111 (94.1) | 28 (49.1) | 22 (45.8) | 13 (33.3) | ||
History of migraine with aura, n (%) | 122 (43.3) | 81 (42.4) | 70 (37.2) | 93 (41.3) | 58 (40.6) | 61 (40.9) | 29 (50.9) | 23 (47.9) | 9 (23.1) |